Clinical laboratory testing in the era of directly acting antiviral therapies for hepatitis C
JournalClinical Microbiology Reviews
PublisherAmerican Society for Microbiology
MetadataShow full item record
AbstractDirectly acting antiviral (DAA) combination therapies for chronic hepatitis C virus (HCV) infection are highly effective, but treatment decisions remain complex. Laboratory testing is important to evaluate a range of viral, host, and pharmacological factors when considering HCV treatment, and patients must be monitored during and after therapy for safety and to assess the viral response. In this review, we discuss the laboratory tests relevant for the treatment of HCV infection in the era of DAA therapy, grouped according to viral and host factors.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84992416909&doi=10.1128%2fCMR.00037-16&partnerID=40&md5=c108123d7c124f448310226de941a9b9; http://hdl.handle.net/10713/11344